• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis
【24h】

Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis

机译：Delanzomib是一种新型蛋白酶体抑制剂，使乳腺癌细胞敏感到多柔比星诱导的细胞凋亡

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Delanzomib, a novel proteasome inhibitor, has demonstrated promising efficacy and antitumor ability in human multiple myeloma cell lines and patient-derived cells. However, the potential therapeutic effects of delanzomib on breast cancer remain unknown. In this study, we show that delanzomib has antitumor effects and synergizes with doxorubicin (Dox) in human breast cancer cell lines. Cell proliferation assay and flow cytometry were used to evaluate cell viability and apoptosis in eight human breast cancer cell lines after treatment with delanzomib or Dox. Essential molecules of the p53, MAPK, and apoptosis signaling pathways were analyzed by Western blotting. Delanzomib induced cell death and demonstrated synergism with Dox in all tested breast cancer cell lines. In addition, delanzomib enhanced the Dox-induced phosphorylation of p38/JNK and the expression of transcriptional target proteins of p53, such as p21, p27, NOXA, and PUMA. The combined regimen of the proteasome inhibitor delanzomib with Dox chemotherapy may become an effective strategy for breast cancer therapy. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译：Delanzomib是一种新型蛋白酶体抑制剂，已经证明了人类多发性骨髓瘤细胞系和患者衍生细胞中的有希望的疗效和抗肿瘤能力。然而，Delanzomib对乳腺癌的潜在治疗效果仍然是未知的。在这项研究中，我们表明Delanzomib具有抗肿瘤效应，并在人乳腺癌细胞系中与多柔比星（DOX）进行促进。细胞增殖测定和流式细胞术用于评估德拉斯佐米或DOX治疗后八种人乳腺癌细胞系中的细胞活力和凋亡。通过蛋白质印迹分析P53，MAPK和凋亡信号传导途径的必需分子。 Delanzomib在所有测试的乳腺癌细胞系中诱导细胞死亡并证明了DOX的协同作用。此外，Delanzomib增强了DOX诱导的P38 / JNK磷酸化，以及P53的转录靶蛋白的表达，例如P21，P27，NOXA和PUMA。蛋白酶体抑制剂Delanzomib与DOX化疗的组合方案可能成为乳腺癌治疗的有效策略。 ？ 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号